U.S. Markets closed

Why Crispr's Gene-Editing Dive Helped Reinvigorate Its Chief Rival, Allogene

·3 min read
Why Crispr's Gene-Editing Dive Helped Reinvigorate Its Chief Rival, Allogene
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped.